Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO
European Journal of Clinical Investigation · 2023
DOI: 10.1111/eci.13963 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2023. Verfasst von Loredana Menninger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, University Hospital, Tübingen, Germany. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Respiratory Distress Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
In severe acute respiratory distress syndrome (ARDS), venovenous extracorporeal membrane oxygenation (vvECMO) can be a lifesaver. However, anticoagulation therapy is mandatory because the nonendothelial extracorporeal surface increases the risk of thromboembolic problems. Heparin is still the most common anticoagulant, but argatroban could be an alternative. This work investigates whether argatroban offers a therapeutic advantage over heparin during vvECMO.
Methods
We performed a retrospective cohort study of patients who underwent vvECMO for severe ARDS and received heparin or argatroban as anticoagulation therapy. Demographic variables, intensive care unit (ICU) treatment and outcome parameters were evaluated. The primary outcome parameter was the operating time of the membrane oxygenator normalized to the duration of vvECMO treatment. Secondary outcome parameters were transfusion requirements normalized to the duration of vvECMO therapy.
Results
Fifty seven patients from January 2019 to February 2021 underwent vvECMO and were included in this study. Thirty three patients received heparin and 24 patients argatroban as anticoagulatory therapy. The groups did not differ in demographics, ICU scoring systems, or comorbidities. Platelet counts and partial prothrombin time did not differ between the two groups during the first 6 days of vvECMO. The argatroban group had lower requirements for red blood cells, platelets and fresh frozen plasma. The mean runtime of the individual membrane oxygenator increased from 12.3 days (heparin group) to 16.6 days in the argatroban group.
Conclusions
Our findings suggest that argatroban can be considered as anticoagulant during vvECMO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Care Medicine, University Hospital, Tübingen, Germany.
- Medical Faculty of Tuebingen, Institute for Clinical and Experimental Transfusion Medicine, Tübingen, Germany.
- Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany.
- Department of Thoracic and Cardiovascular Surgery, University Hospital Tübingen, Tübingen, Germany.
ORCID-Profile: Michael Koeppen
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Menninger, L., Körner, A., Mirakaj, V., Heck-Swain, K. L., Haeberle, H. A., Althaus, K., Baumgaertner, M., Jost, W., Schlensak, C., Rosenberger, P., & Koeppen, M. (2023). Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.13963
Vancouver
Menninger L, Körner A, Mirakaj V, Heck-Swain KL, Haeberle HA, Althaus K, et al. Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO. European Journal of Clinical Investigation. 2023. doi:10.1111/eci.13963
BibTeX
@article{Menninger2023,
author = {Menninger, Loredana and Körner, Andreas and Mirakaj, Valbona and Heck-Swain, Ka-Lin and Haeberle, Helene A and Althaus, Karina and Baumgaertner, Michael and Jost, Walter and Schlensak, Christian and Rosenberger, Peter and Koeppen, Michael},
title = {Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO},
journal = {European Journal of Clinical Investigation},
year = {2023},
doi = {10.1111/eci.13963}
}
EUVIMED